Exelixis
EXEL
#2109
Rank
$7.53 B
Marketcap
$26.42
Share price
-1.53%
Change (1 day)
22.83%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Cash on Hand

Cash on Hand as of June 2024 : $1.00 B

According to Exelixis's latest financial reports the company has $1.00 B in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Exelixis - Cash on Hand chart (from 2000 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31$0.99 B-23.93%
2022-12-31$1.30 B-10.81%
2021-12-31$1.46 B21.59%
2020-12-31$1.20 B41.57%
2019-12-31$0.85 B22.92%
2018-12-31$0.69 B78.8%
2017-12-31$0.38 B-7.63%
2016-12-31$0.41 B151.29%
2015-12-31$0.16 B15.78%
2014-12-31$0.14 B-40.49%
2013-12-31$0.24 B-41.07%
2012-12-31$0.41 B111.8%
2011-12-31$0.19 B19.43%
2010-12-31$0.16 B-19.9%
2009-12-31$0.20 B-22.6%
2008-12-31$0.26 B-3.37%
2007-12-31$0.27 B51.8%
2006-12-31$0.17 B20.35%
2005-12-31$0.14 B-4.22%
2004-12-31$0.15 B-34.55%
2003-12-31$0.23 B6.8%
2002-12-31$0.22 B-2.51%
2001-12-31$0.22 B102.31%
2000-12-31$0.11 B1531.19%
1999-12-31$6.9 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
$3.77 B 276.67%๐Ÿ‡ฌ๐Ÿ‡ง UK
$7.28 B 626.96%๐Ÿ‡ซ๐Ÿ‡ท France
$11.35 B 1,033.13%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.65 B 563.97%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.30 B 828.24%๐Ÿ‡บ๐Ÿ‡ธ USA
$25.47 B 2,442.42%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.10 B 608.68%๐Ÿ‡บ๐Ÿ‡ธ USA
$28.36 M-97.17%๐Ÿ‡บ๐Ÿ‡ธ USA
$77.39 M-92.28%๐Ÿ‡บ๐Ÿ‡ธ USA